Toggle Main Menu Toggle Search

Open Access padlockePrints

Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil

Lookup NU author(s): Dr David Jamieson, Dr Jo Lee, Dr Nicola Cresti, Melanie Griffin, Julieann Sludden, Dr Mark Verrill, Professor Alan Boddy

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Most adjuvant breast cancer treatment regimens include the combination of an anthracycline (epirubicin or doxorubicin) and the alkylating agent cyclophosphamide. This study sought to investigate the influence of pharmacogenetics on the pharmacokinetics and metabolism of these agents.Blood samples were taken from patients treated with cyclophosphamide (n = 51) and epirubicin (n = 35), with or without 5-fluorouracil (5-FU). The pharmacokinetics and metabolism of the three drugs were investigated, together with pharmacogenetic investigations for cyclophosphamide and epirubicin. Cyclophosphamide and its metabolites and also epirubicin and epirubicinol were measured in plasma. DNA was extracted from whole blood and genotyping performed using RT-PCR.Patients with at least one variant CYP2C19*17 allele had a longer CP half-life (p = 0.007), as did homozygous variants for the CYP2B6*6 allele. There was no significant effect of GSTP1, CYP2B6*2, CYP2B6*5 or CYP2C19*2 on any pharmacokinetic parameter of CP. An NQO2 exonic SNP was associated with a higher exposure to epirubicinol relative to epirubicin (p = 0.011). Other polymorphic variants of NQO1, carbonyl reductase, UGT enzymes and transporters had no influence on epirubicin or its metabolite.Overall, pharmacogenetic factors had only a minor influence on cyclophosphamide or anthracycline-based adjuvant therapy of breast cancer.


Publication metadata

Author(s): Jamieson D, Lee J, Cresti N, Jackson R, Griffin M, Sludden J, Verrill M, Boddy AV

Publication type: Article

Publication status: Published

Journal: Cancer Chemotherapy and Pharmacology

Year: 2014

Volume: 74

Issue: 4

Pages: 667-674

Print publication date: 01/10/2014

Online publication date: 24/07/2014

Acceptance date: 11/07/2014

ISSN (print): 0344-5704

ISSN (electronic): 1432-0843

Publisher: Springer

URL: http://dx.doi.org/10.1007/s00280-014-2541-6

DOI: 10.1007/s00280-014-2541-6


Altmetrics

Altmetrics provided by Altmetric


Actions

Find at Newcastle University icon    Link to this publication


Share